A recent study published in the Journal of the American Geriatrics Society found that 61 percent of participants – all 65-and-older – started using cannabis after age 60 with 53 percent of the 568 surveyed saying they used cannabis on a daily or weekly basis.
The latest psychedelic drug company to commence public trading is Psyched Wellness.
The Massachusetts Cannabis Control Commission on Tuesday approved regulations for expanded cannabis home delivery, the Boston Globe reports.
Mind Cure has acquired Epiphany360, a digital therapeutics platform for the treatment of mental health conditions.
Psychedelic drug stocks may represent the best investing strategy to hedge against COVID-19 economic risks.
Revive has signed a psychedelics supply agreement with HAVN Life Sciences.
Texas stands to generate billions of dollars in marijuana tax revenue and create tens of thousands of jobs if the plant is legalized, according to a new economic analysis.
Pharmather is seeking to advance a ketamine-based therapy for the treatment of Parkinson's disease.
New Jersey is poised to join the growing number of states to legalize recreational marijuana use when voters head to the polls next month, according to a new survey out this week.
The top Democrat in the Senate introduced a coronavirus relief bill on Monday that contains provisions to protect banks that service state-legal marijuana businesses from being penalized by federal regulators.
The Compass Pathways IPO was a huge catalyst for the whole sector. Will a MindMed up-listing have the same impact?
Cybin Corp. announces it has closed on an oversubscribed private placement of CAD$45 million as it prepares to go public.
The U.S. Department of Agriculture (USDA) has signed off on hemp plans for six additional states and three Indian tribes this month, with a new batch of approvals coming on Friday.
Missouri’s medical cannabis market launched over the weekend, with a pair of retail outlets outside St. Louis seeing long patient lines in a state where MMJ sales could hit an estimated $650 million a year by 2024.
The business outlook for cannabis companies could be significantly different this time next year, depending in large part on which party controls the Senate and which senators are elected.
